Supportive care in pancreatic ductal adenocarcinoma

被引:20
|
作者
Laquente, B. [1 ]
Calsina-Berna, A. [2 ]
Carmona-Bayonas, A. [3 ]
Jimenez-Fonseca, P. [4 ]
Peiro, I. [5 ]
Carrato, A. [6 ]
机构
[1] Inst Catalan Oncol, Dept Med Oncol, Av Gran Via 199-203, Barcelona 0898, Spain
[2] Hosp Germans Trias I Pujol, Inst Catalan Oncol, Dept Palliat Care, Badalona, Spain
[3] Hosp Univ Morales Meseguer, Dept Med Oncol & Hematol, Murcia, Spain
[4] Hosp Univ Cent Asturias, Dept Med Oncol, Oviedo, Spain
[5] Inst Catalan Oncol, Clin Nutr Unit, Barcelona, Spain
[6] Hosp Univ Ramn y Cajal, Dept Med Oncol, Madrid, Spain
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2017年 / 19卷 / 11期
关键词
Supportive care; Pancreatic ductal adenocarcinoma; Symptoms; Biliary obstruction; Cachexia; Thromboembolic disease; MOLECULAR-WEIGHT HEPARIN; DISTAL BILIARY OBSTRUCTION; VISCERAL CANCER PAIN; VENOUS THROMBOEMBOLISM; TISSUE FACTOR; AMERICAN SOCIETY; ESPEN GUIDELINES; SURGICAL BYPASS; PALLIATIVE CARE; METAL STENTS;
D O I
10.1007/s12094-017-1682-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with poorest prognosis and represents the third leading cause of cancer-related deaths in Western countries. Despite advances in diagnostic procedures and treatment, diagnosis is made in most cases when the disease is locally advanced or metastatic. Supportive care aims to improve symptoms, reduce hospital admission rates, and preserve quality of life. Proper symptomatic management is critical to allow administration of chemotherapy and radiotherapy. Symptomatic management should be accomplished in a multidisciplinary fashion. Its primary aims include relief of biliary or duodenal obstruction, prevention and/or treatment of thromboembolic disease, and control cancer-related pain. Nutritional support and optimal replacement therapy in patients with endocrine and/or exocrine insufficiency, is mandatory. This manuscript highlights the most significant problems faced when caring for patients with advanced PDAC and provides an evidence-based approach to symptomatic management.
引用
收藏
页码:1293 / 1302
页数:10
相关论文
共 50 条
  • [11] Pancreatic ductal adenocarcinoma associated with pancreatic ductal intraepithelial neoplasia
    Umesh K Bhanot
    Hepatobiliary&PancreaticDiseasesInternational, 2008, (01) : 106 - 107
  • [12] Pancreatic ductal adenocarcinoma associated with pancreatic ductal intraepithelial neoplasia
    Bhanot, Umesh K.
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2008, 7 (01) : 106 - 107
  • [13] Surgery for pancreatic ductal adenocarcinoma
    Vera, R.
    Diez, L.
    Martin Perez, E.
    Plaza, J. C.
    Sanjuanbenito, A.
    Carrato, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (11): : 1303 - 1311
  • [14] Models of pancreatic ductal adenocarcinoma
    Dennaoui, Rayane
    Shrestha, Hridaya
    Wagner, Kay-Uwe
    CANCER AND METASTASIS REVIEWS, 2021, 40 (03) : 803 - 818
  • [15] MicroRNAs in pancreatic ductal adenocarcinoma
    Park, Jong Y.
    Helm, James
    Coppola, Domenico
    Kim, Donghwa
    Malafa, Mokenge
    Kim, Seung Joon
    WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (07) : 817 - 827
  • [16] Hypoxia and pancreatic ductal adenocarcinoma
    Yamasaki, Akio
    Yanai, Kosuke
    Onishi, Hideya
    CANCER LETTERS, 2020, 484 : 9 - 15
  • [17] Macrophages and pancreatic ductal adenocarcinoma
    Habtezion, Aida
    Edderkaoui, Mouad
    Pandol, Stephen J.
    CANCER LETTERS, 2016, 381 (01) : 211 - 216
  • [18] Staging of pancreatic ductal adenocarcinoma
    Sauvanet, A
    Zins, M
    JOURNAL DE CHIRURGIE, 1998, 135 (01): : 10 - 16
  • [19] FOLFIRINOX for Pancreatic Ductal Adenocarcinoma
    Alakus, Hakan
    Korenkov, Michael
    Kuetting, Fabian
    Bruns, Christiane
    ONKOLOGE, 2019, 25 (08): : 726 - 727
  • [20] Immunotherapy for pancreatic ductal adenocarcinoma
    Carpenter, Eileen
    Nelson, Sarah
    Bednar, Filip
    Cho, Clifford
    Nathan, Hari
    Sahai, Vaibhav
    di Magliano, Marina Pasca
    Frankel, Timothy L.
    JOURNAL OF SURGICAL ONCOLOGY, 2021, 123 (03) : 751 - 759